🏥 Health 10h ago

View Channel →

0 0 Save Read Full Article Source ↗ 👁 0 💬 0

(MedPage Today) -- An oral peptide that blocks the interleukin-23 receptor demonstrated durable long-term efficacy in patients with moderately to severely active ulcerative colitis, according to results from the phase IIb ANTHEM-UC trial.
During...

Sign in to join the discussion

📰

Ozempic and Wegovy linked to rare risk of sudden vision loss

Health & Medicine News -- ScienceDaily · 2h ago

📰

A 47-year study reveals the age when your body starts losing strength

Health & Medicine News -- ScienceDaily · 6h ago

Compass Pathways CEO: Psychedelics company will ‘go slow before we go fast’

STAT · 7h ago

Former FDA officials blast DOGE as ‘one of the biggest disasters in American history’

STAT · 7h ago

As White House shifts focus toward AI and tech, U.S. science leaders defend role of the American university

STAT · 8h ago

📰

Cancer is rising in younger adults, and scientists can't fully explain why

Health & Medicine News -- ScienceDaily · 9h ago